October 3, 2024 03:00 AM EDTUpdated 06:52 AM
Financing
Startups

In­vestor Kur­ma Part­ners rais­es €140M for lat­est Eu­rope-fo­cused biotech fund

Kyle LaHucik

Senior Reporter

Kur­ma Part­ners has closed the first part of its lat­est biotech-fo­cused fund, fol­low­ing a pair of M&A ex­its for drug de­vel­op­ers backed by its third …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

BioN­Tech opens the hood on its AI am­bi­tions, and they're not just for mR­NA

EMA looks to make its drug ap­proval process­es more ef­fi­cient

Ex­clu­sive: Af­ter dis­cov­er­ing an­tibi­otics with AI, a 31-year-old first-time CEO rais­es $17M to fight ag­ing

Lil­ly in­vests $4.5B in new In­di­ana site to bring clin­i­cal man­u­fac­tur­ing in-house

Scoop: Found­ing CEO leaves Atom­wise, cast­ing doubt over a once high-fly­ing AI start­up 

sponsored

3 Tiers for AAV Po­ten­cy As­say De­vel­op­ment Suc­cess

A service from the Financial Times